» Articles » PMID: 23355209

Colorimetric in Situ Hybridization Identifies MYC Gene Signal Clusters Correlating with Increased Copy Number, MRNA, and Protein in Diffuse Large B-cell Lymphoma

Abstract

Abnormalities of the MYC oncogene on chromosome 8 are characteristic of Burkitt lymphoma and other aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We recently described a colorimetric in situ hybridization (CISH) method for detecting extra copies of the MYC gene in DLBCL and the frequent occurrence of excess copies of discrete MYC signals in the context of diploidy or polyploidy of chromosome 8, which correlated with increased mRNA signals. We further observed enlarged MYC signals, which were counted as a single gene copy but, by their dimension and unusual shape, likely consisted of "clusters" of MYC genes. In this study, we sought to further characterize these clusters of MYC signals by determining whether the presence of these correlated with other genetic features, mRNA levels, protein, and overall survival. We found that MYC clusters correlated with an abnormal MYC locus and with increased mRNA. MYC mRNA correlated with protein levels, and both increased mRNA and protein correlated with poorer overall survival. MYC clusters were seen in both the germinal center and activated B-cell subtypes of DLBCL. Clusters of MYC signals may be an underappreciated, but clinically important, feature of aggressive B-cell lymphomas with potential prognostic and therapeutic relevance.

Citing Articles

Chromogenic mRNA ISH Expression Correlates with LMO2 Protein and Gene Expression and Captures Their Survival Impact in Diffuse Large B-Cell Lymphoma, NOS.

Papaleo N, Molina-Alvarez A, Onieva R, Fuertes D, Sanchez-Gonzalez B, Riera X Cancers (Basel). 2024; 16(13).

PMID: 39001439 PMC: 11240605. DOI: 10.3390/cancers16132378.


Genomic Analysis of Lymphoma Risk in Bullmastiff Dogs.

Mortlock S, Asada M, Soh P, Hsu W, Lee C, Bennett P Vet Sci. 2023; 10(12).

PMID: 38133254 PMC: 10747964. DOI: 10.3390/vetsci10120703.


Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma.

Xu Y, Jenjaroenpun P, Wongsurawat T, Byrum S, Shponka V, Tannahill D NAR Cancer. 2020; 2(4):zcaa029.

PMID: 33094287 PMC: 7556405. DOI: 10.1093/narcan/zcaa029.


Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV.

Shponka V, Reveles C, Alam S, Jaramillo M, Maguire A, Rimsza L AIDS. 2020; 34(14):2025-2035.

PMID: 32773475 PMC: 9306295. DOI: 10.1097/QAD.0000000000002653.


An increase in copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.

Schieppati F, Balzarini P, Fisogni S, Re A, Pagani C, Bianchetti N Haematologica. 2019; 105(5):1369-1378.

PMID: 31399522 PMC: 7193495. DOI: 10.3324/haematol.2019.223891.


References
1.
Slack G, Gascoyne R . MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011; 18(3):219-28. DOI: 10.1097/PAP.0b013e3182169948. View

2.
Yoon S, Jeon Y, Paik J, Kim W, Kim Y, Kim J . MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008; 53(2):205-17. DOI: 10.1111/j.1365-2559.2008.03076.x. View

3.
Silva T, Lima P, Bahia M, Khayat A, Bezerra F, Andrade-Neto M . Pisosterol induces interphase arrest in HL60 cells with c-MYC amplification. Hum Exp Toxicol. 2010; 29(3):235-40. DOI: 10.1177/0960327109359637. View

4.
Savage K, Johnson N, Ben-Neriah S, Connors J, Sehn L, Farinha P . MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009; 114(17):3533-7. DOI: 10.1182/blood-2009-05-220095. View

5.
Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R . Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28(20):3360-5. DOI: 10.1200/JCO.2009.26.3947. View